How Salmonella bacteria use DMSO to thrive in the gut
Official title: Differential regulation of three DMSO reductases during enteric salmonellosis
Funded at University of Wisconsin-Madison · NIH-10897765 · Data updated 2026-11-12
This study looks at how certain bacteria, called non-typhoidal Salmonella, use a substance called DMSO to help them survive and grow in our guts, and it aims to learn more about how these bacteria adapt when they infect us.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $38,466 |
| NIH project number | 5F30AI169967-02 |
| Project ID | NIH-10897765 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who have experienced or are at risk for infections caused by non-typhoidal Salmonella.
✕Less likely to help
Patients with infections caused by other pathogens or those not affected by enteric diseases may not benefit from this research.
What this research studies
This research investigates how non-typhoidal Salmonella bacteria utilize dimethyl sulfoxide (DMSO) to enhance their survival and growth in the mammalian gut. By studying the genetic mechanisms that regulate three different DMSO reductases in Salmonella, the research aims to understand how these bacteria adapt to varying nutrient conditions during infection. The approach involves using laboratory models to analyze the function and regulation of these reductases, which could provide insights into bacterial behavior during enteric infections.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating infections caused by Salmonella, improving patient outcomes.
How similar studies have gone: Previous research has shown that understanding bacterial metabolic pathways can lead to significant advancements in treating infections, suggesting this approach has potential for success.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Cruz, Eddy — University of Wisconsin-Madison
- Study coordinator: Cruz, Eddy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.